Drug Type Small molecule drug |
Synonyms BHV 5000 |
Target |
Mechanism NMDA receptor antagonists(Glutamate [NMDA] receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC27H34N4O6 |
InChIKeyOOWJWLVORHEGOA-OFSTUUFMSA-N |
CAS Registry1772581-18-6 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Rett Syndrome | Phase 1 | US | 21 Jan 2021 | |
Complex Regional Pain Syndromes | Phase 1 | US | 05 Dec 2018 | |
Depressive Disorder, Major | Preclinical | US | 23 Jan 2021 |